Viatris Reports Q2 2026 Revenue Growth to $3.76 Billion Despite Net Loss

Viatris Inc. reported its financial results for the second quarter of 2026, revealing total revenues of $3.76 billion, a 5% increase from $3.58 billion in the same period last year. Net sales for the quarter reached $3.75 billion, up from $3.57 billion, driven by new product sales and growth in key markets. The company recorded a gross profit of $1.46 billion, resulting in a gross margin of 39%, compared to 37% in the prior year. However, Viatris experienced a net loss of $118.8 million, compared to a loss of $4.6 million in the same quarter of 2025, leading to a diluted loss per share of $0.10.

For the first half of 2026, Viatris reported total revenues of $7.27 billion, a 6% increase from $6.84 billion in the prior year. Net earnings for the period were $57.6 million, a significant recovery from a net loss of $3.05 billion in the first half of 2025, which included a substantial goodwill impairment charge. The company’s adjusted EBITDA for the first half was $1.19 billion, reflecting ongoing operational improvements despite challenges in certain markets.

Strategically, Viatris has been active in restructuring efforts, initiating a comprehensive review aimed at optimizing its operations. The company expects to incur total pre-tax charges of between $700 million and $850 million related to these restructuring activities, which include a global workforce reduction of up to 10%. Additionally, Viatris has been involved in divesting certain product rights, including a planned sale of Tyrvaya® for $30 million, which is expected to impact its financials in the near term.

Operationally, Viatris has faced challenges, particularly with its manufacturing facilities. A fire at its Nashik facility in India led to temporary production halts and subsequent remediation efforts, which are anticipated to affect product supply and revenue in the latter half of 2026. The company has also been engaged in various legal proceedings, including ongoing litigation related to opioid sales and antitrust claims, which could have material financial implications.

Looking ahead, Viatris remains focused on leveraging its global footprint and diverse product portfolio to drive growth. The company anticipates continued revenue growth from new product launches and market expansion, particularly in Greater China, where net sales increased by 21% in the second quarter. However, it also acknowledges potential risks from regulatory challenges, market competition, and ongoing legal matters that could impact its financial performance.